Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
Philipp Berning(University Hospital Münster), Bertram Glaß(Helios Hospital Berlin-Buch), Avichai Shimoni, Dai‐Hong Liu(Chinese PLA General Hospital), Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges), Javier López Jiménez(Hospital Universitario Ramón y Cajal), Gerald Wulf(University of Göttingen), Hans Christian Reinhardt(German Cancer Research Center), Ben Carpenter(The Royal Free Hospital), Xiao‐Jun Huang(Peking University), Jaime Sanz(Hospital Universitari i Politècnic La Fe), Mi Kwon(Hospital General Universitario Gregorio Marañón), Feng‐Rong Wang(Anhui University), Ibrahim Yakoub‐Agha(Inserm), Maud Ngoya, Lucile Couronné(Inserm), Hervé Finel, Olivier Hermine(Centre National de la Recherche Scientifique), Laure Philippe(Assistance Publique – Hôpitaux de Paris), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Peter Dreger(Heidelberg University), Yves Chalandon(University of Geneva), Hélène Labussière‐Wallet(Hospices Civils de Lyon), Xi Zhang(Army Medical University), Won-Seog Kim(Samsung Medical Center), Depei Wu(Soochow University), Ariane Boumendil(Inserm), Eva Wagner(Johannes Gutenberg University Mainz), Norbert Schmitz(University Hospital Münster)
Cited by 0
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
|Journal of Clinical Oncology|2012|965
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859